Malignant hypercalcemia is the main metabolic complication of cancer. Clinical presentation varies from asymptomatic to a medical emergency. The main causes include parathyroid hormone-related protein production and bone metastases, while hypervitaminosis D and hyperparathyroidism are rarer causes. Diagnosis is based on the demonstration of elevated serum calcium and low PTH in the context of known or suspected cancer. Treatment is aimed at correcting hypovolemia by hydration, reducing bone resorption, and treating the underlying cancer. The aims are to improve patients' quality of life, minimize delays in oncological management and reduce mortality associated with this condition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.53738/REVMED.2024.20.892.1952 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Not Available].
Tunis Med
December 2024
Felix Houphouët Boigny University - Medical Sciences Department .Rheumatology Department, Cocody University Hospital, Abidjan, Republic of Côte d'Ivoire.
Aim: describe the epidemiological, clinical, etiological and therapeutic aspects of hypercalcemia seen in the rheumatology department of Cocody University Hospital.
Methods: Descriptive cross-sectional study carried out in the rheumatology department of Cocody University Hospital from January 2013 to July 2022 and covering the files of patients with hypercalcemia.
Results: The hospital frequency of hypercalcemia was 0.
Parathyroid carcinoma: New insights.
Best Pract Res Clin Endocrinol Metab
December 2024
Obesity, Type 2 Diabetes and Immunometabolism Research Group, School of Cardiovascular and Metabolic Medicine & Sciences, Faculty of Life Course Sciences, King's College London, London, UK; Division of Biomedical Sciences, Reproductive Health, Warwick Medical School, University of Warwick, Coventry, UK. Electronic address:
Parathyroid carcinoma (PC) is a rare malignancy, comprising 1 % of all cases of primary hyperparathyroidism (PHPT). This narrative review explores recent advances in PC management, with a focus on molecular insights, diagnostic advancements, surgical innovations, and emerging targeted therapies. Manuscripts published between 2023 and 2024 were obtained from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL).
View Article and Find Full Text PDFDe Novo Hypercalcaemia in a Patient With Chronic Hypoparathyroidism.
Cureus
December 2024
Endocrinology, Mallow General Hospital/University College Cork, Cork, IRL.
Calcium Homeostasis in the human body is regulated by hormones, including parathyroid hormone and vitamin D3. Dysfunction in the form of hypoparathyroidism causes hypocalcaemia. In patients treated for primary hypoparathyroidism with activated vitamin D replacement, iatrogenic hypercalcaemia can occur.
View Article and Find Full Text PDFIs There Anything New in Canine AGASACA?
Vet Sci
December 2024
Department of Veterinary Medical Sciences, University of Parma, Strada del Taglio 10, 43126 Parma, Italy.
Apocrine gland anal sac adenocarcinoma (AGASACA) is a locally invasive tumor with a high potential for early metastasis. The most recent studies indicate that 23.4-83% of dogs have metastases to the iliosacral lymph nodes (LNs), and 2.
View Article and Find Full Text PDFImaging Findings of an Unusual Malignant Renal Tumor in an Infant.
Cureus
November 2024
Radiology, State University of New York Upstate Medical University, Syracuse, USA.
Malignant rhabdoid tumor is a rare highly aggressive neoplasm that affects young children. It is composed of stromal and epithelial components and commonly arises from the kidney. The clinical presentation is usually nonspecific, and the common signs are palpable abdominal mass, hematuria, fever, anemia, and hypercalcemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!